Please ensure Javascript is enabled for purposes of website accessibility

Why Compass Pathways Shares Are Slumping More Than 22% Tuesday

By Jim Halley – Nov 9, 2021 at 3:48PM

Key Points

  • The company announced positive news out of its phase IIB trial for its lead therapy.
  • Compass Pathways also released third-quarter numbers showing it lost less money than it did in the same period a year ago.
  • Investors may have been taking profits on the good news, driving the stock's price down.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The stock dropped more than $13 on Tuesday.

What happened 

Compass Pathways (CMPS -5.25%) saw its shares drop more than 22% on Tuesday. The biotech stock, which focuses on mental health treatment, closed at $43.06 on Monday, opened at $40.65 on Tuesday and fell as low as $30.52 in midday trading. The stock, which is down more than 6.5% for the year, has been as high as $61.69 and as low as $28.58 over the past 52 weeks. 

So what 

Two announcements by the company weighed on the stock price, though ironically, both were mostly positive.  

The first was related to its lead therapy for treatment-resistant depression. The company, which had its IPO last year, said its phase IIB clinical trial of its COMP360 psilocybin therapy for depression showed that at its highest dosage (25mg), COMP360 found a reduction in depressive symptoms after three weeks. The drug's primary ingredient, psilocybin, is the active molecule in so-called psychedelic magic mushrooms.

A person sitting on floor with back against couch and looking down.

Image source: Getty Images.

The catch for some investors may have been that side effects were relatively common. Compass said that 179 of the 233 trial participants had treatment-emergent adverse events, but the company said all but 12 of the events were mild side effects, such as nausea, headaches, fatigue and insomnia. Compass said it plans to start a phase 3 trial for COMP360 in 2022. 

The second announcement was the company's third-quarter earnings report. It does not yet have marketed products, so it has no income. Through nine months, the company said it lost $46.1 million, or $1.17 per share, compared with a loss of $41.5 million, or $3.90 a share in the same period in 2020.

Now what 

It was a classic case of investors selling into positive news that drove the biotech stock down. A lot of the good news from the trial had been expected, so it was, in effect, baked into the stock's price. Until Monday, the stock had not been near $50 a share since February, and investors gladly unloaded their shares.  

That may be bad news for short-term investors, but the long-term outlook for Compass is on the upswing. As of Sept. 30, the company has 49.6% more cash -- $294 million -- than it did at this time last year. And it's possible, with a successful phase 3 trial, the company could begin marketing COMP360 sometime next year or early 2023 -- meaning, it would finally have income.  

Jim Halley has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends COMPASS Pathways plc. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.